Abstract
Background Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone r......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
